Pathophysiological implications of insulin resistance on vascular endothelial function

Diabetic Medicine

Volumn 20, Issue 4, 2003, Pages 255-268

  Wheatcroft, Stephen B ^a   Williams, I L ^a   Shah, A M ^a   Kearney, M T ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Atherosclerosis; Endothelial dysfunction; Insulin resistance; Nitric oxide; Type 2 diabetes mellitus

Indexed keywords

CYTOKINE; ENDOTHELIN; HORMONE; NITRIC OXIDE; SUPEROXIDE; VASOACTIVE AGENT;

ADIPOSE TISSUE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CYTOKINE RELEASE; HIGH RISK PATIENT; HORMONE RELEASE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELINS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERINSULINISM; INSULIN RESISTANCE; NITRIC OXIDE; RENIN-ANGIOTENSIN SYSTEM;

EID: 0037900056     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2003.00869.x     Document Type: Review

References (229)

1. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48: 937-942.
2. Hsueh WA, Law RE. Cardiovascular risk continuum: implications of insulin resistance and diabetes. Am J Med 1998; 105: 4S-14S.
3. Zimmet P, Alberti K. The changing face of macrovascular disease in non-insulin dependent diabetes mellitus in different cultures: an epidemic in progress. Lancet 1997; 350: S1-S4.
4. Haffner SM, Stern M, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes. JAMA 1990; 263: 2893-2898.
5. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
6. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486-2497.
7. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 187: 356-259.
8. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957.
9. Pyorala M, Miettinen H, Halonen P, Laakso M, Pyorala K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol 2000; 20: 538-544.
10. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
11. Luscher TF. The endothelium and cardiovascular disease - a complex relation. N Engl J Med 1994; 330: 1081-1083.
12. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906.
13. Vanhoutte PM. Endothelial dysfunction and vascular disease. In Panza JA, Cannon RO eds. Endothelium, Nitric Oxide, and Atherosclerosis. Armonk, NY: Futura Publishing, 1999.
14. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997; 100: 2153-2157.
15. Arnold W, Mittal C, Katsuki S, Murad F. Nitric oxide activates gunanylate cyclase and increases guanosine 3,5-cyclic monophosphate in various tissue preparations. Proc Natl Acad Sci USA 1977; 74: 3203-3207.
16. Lincoln T, Cornwell T. Intracellular cyclic GMP receptor proteins. FASEB J 1993; 7: 328-338.
17. Endo T, Imaizumi T, Tagawa T, Shiramoto M, Ando S, Takeshita A. Role of nitric oxide in exercise induced vasodilation in the forearm. Circulation 1994; 90: 2886-2890.
18. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase. Role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.
19. Andrew P, Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc Res 1999; 43: 521-531.
20. Fleming I, Busse R. Signal transduction of eNOS activation. Cardiovasc Res 1999; 43: 532-541.
21. Xia Y, Dawson VL, Dawson TM, Snyder SH, Zweier JL. Nitric oxide synthase generates superoxide and nitric oxide in arginine depleted cells leading to peroxynitrite-mediated cellular injury. Proc Natl Acad Sci USA 1996; 93: 6770-6774.
22. Wever R, Luscher T, Consentino F, Rabelink TJ. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 1998; 97: 108-112.
23. Papapetropoulos A, Rudic RD, Sessa WC. Molecular control of nitric oxide synthases in the cardiovascular system. Cardiovasc Res 1999; 43: 509-520.
24. Zembowicz A, Tang J, Wu K. Transcriptional induction of endothelial nitric oxide synthase type III by lysophosphatidyl choline. J Biol Chem 1995; 270: 17006-17010.
25. Awolesi M, Sessa WC, Sumpio B. Cyclic strain upregulates nitric oxide synthase in cultured bovine aortic endothelial cells. J Clin Invest 1995; 96: 1449-1454.
26. Sessa WC, Pritchard K, Seyedi N, Wang J, Hintze TH. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide gene expression. Circ Res 1994; 74: 349-353.
27. Bouloumie A, Schinikerth V, Busse R. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res 1999; 41: 773-780.
28. Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 2000; 101: 676-681.
29. Hirata K, Miki N, Kuroda Y, Sakoda T, Kawashima S, Yokoyama M. Low concentrations of oxidised low-density lipoprotein and lysophosphatidyl choline upregulate constitutive nitric oxide synthase mRNA expression in bovine aortic endothelial cells. Circ Res 1995; 76: 958-962.
30. Nishida K, Harrison DG, Navas J, Fisher A, Dockery S, Uematsu M et al. Molecular cloning and characterisation of the constitutive bovine endothelial cell nitric oxide synthase. J Clin Invest 1992; 90: 2092-2096.
31. McQuillian L, Leung G, Marsden P, Kostyk S, Kourembanas S. Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms. Am J Physiol - Heart Circulatory Physiol 1994; 267: H1921-H1927.
32. Laufs U, La Fata V, Plutzky J, Liao J. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-1135.
33. Ziegler T, Silacci P, Harrison V, Hayoz D. Nitric oxide synthase expression in endothelial cells exposed to mechanical forces. Hypertension 1998; 32: 351-355.
34. Liao J, Shin W, Lee W, Clark S. Oxidised low density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995; 270: 319-324.
35. Yoshzumi M, Perella M, Burnett J, Lee M. Tumour necrosis factor downregulates endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993; 73: 205-209.
36. Govers R, Rabelink TJ. Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol 2001; 280: F193-206.
37. Gosink E, Forsberg E. Effects of ATP and bradykinin on endothelial cell calcium homeostasis and formation of cGMP and prostacyclin. Am J Physiol Cell Physiol 1993; 265: C1620-1629.
38. Michel T, Feron O. Nitric oxide synthases: which, where, how, and why? J Clin Invest 1997; 100: 2146-2152.
39. Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000; 101: 1539-1545.
40. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher A. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399: 601-605.
41. Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 1999; 104: 447-457.
42. Shaul P, Smart E, Robinson L. Acylation targets endothelial nitric oxide synthase to plasmalemmal caveolae. J Biol Chem 1996; 271: 6518-6522.
43. Garcia-Cardena G, Oh P, Liu J, Schnitzer J, Sessa WC. Targeting of nitric oxide synthase to endothelial caveolae via palmitoylation; implications for nitric oxide signalling. Proc Natl Acad Sci USA 1996; 93: 6448-6453.
44. de Weerd W, Leeb-Lundberg L. Bradykinin sequesters B2 bradykinin receptors and the receptor coupled G subunits Gq and Gi in caveolae in DDT1 MF-2 smooth muscle cells. J Biol Chem 1997; 272: 17858-17866.
45. Fujimoto T. Calcium pump of the plasma membrane is localised in caveolae. J Cell Biol 1993; 120: 1147-1157.
46. McDonald K, Zharikov S, Block E, Kilberg M. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric oxide synthase may explain the 'arginine paradox'. J Biol Chem 1997; 272: 31213-31216.
47. Gustavsson J, Parpal S, Karlsson M, Ramsing C, Thorn H, Borg M et al. Localisation of the insulin receptor in caveolae of adipocyte plasma membrane. FASEB J 1999; 13: 1961-1971.
48. Gratton JP, Fontana J, O'Connor DS, Garcia-Cardena G, McCabe TJ, Sessa WC. Reconstitution of an endothelial nitric-oxide synthase (eNOS), hsp90, and caveolin-1 complex in vitro. Evidence that hsp90 facilitates calmodulin stimulated displacement of eNOS from caveolin-1. J Biol Chem 2000; 275: 22268-22272.
49. Ju H, Zou R, Venema VJ, Venema RC. Direct interaction of endothelial nitric oxide synthase and caveolin-1 inhibits synthase activity. J Biol Chem 1997; 272: 18522-18525.
50. Michel JB, Feron O, Sacks D, Michel T. Reciprocal regulation of endothelial nitric oxide synthase by Ca-calmodulin and caveolin. J Biol Chem 1997; 272: 15583-15586.
51. Rosbinson L, Michel T. Mutagenesis of palmitoylation sites in endothelial nitric oxide synthase identifies a novel motif for dual acylation and subcellular targetting. Proc Natl Acad Sci USA 1995; 92: 11776-11780.
52. Feron O, Saldana F, Michel JB, Michel T. The endothelial nitric-oxide synthase-caveolin regulatory cycle. J Biol Chem 1998; 273: 3125-3128.
53. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases. The role of oxidant stress. Circ Res 2000; 87: 840-844.
54. Laight DW, Carrier MJ, Anggard EE. Antioxidants, diabetes and endothelial dysfunction. Cardiovasc Res 2000; 47: 457-464.
55. White CR, Brock TA, Chang L-Y, Crapo J, Briscoe P, Ku D et al. Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 1044-1048.
56. Salvemini D, Radziszewski W, Molace V, Moore A, Willoughby D, Vane J. Diphenylene iodonium, an inhibitor of free radical formation, inhibits platelet aggregation. Eur J Pharmacol 1991; 199: 15-18.
57. Chatterjee S. Sphingolipids in atherosclerosis and vascular biology. Arterioscler, Thromb Vasc Biol 1998; 18: 1523-1533.
58. Weber C, Erl W, Pietsch A, Strobel M, Weber P. Antioxidants inhibit monocyte adhesion by suppressing nuclear factor-kappa B mobilization and induction of vascular cell adhesion molecule-1 in endothelial cells stimulated to generate radicals. Arteriosclerosis, Thrombosis Vascular Biol 1994; 14: 1665-1673.
59. Mohazzab KM, Kaminski PM, Wolin MS. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol 1994; 266: H2568-H2572.
60. Kashiwagi A, Shinozaki K, Nishio Y, Okamura T, Toda N, Kikkawa R. Free radical production in endothelial cells as a pathogenetic factor for vascular dysfunction in the insulin resistance state. Diabetes Res Clin Pract 1999; 45: 199-203.
61. Thrasher AJ, Keep NH, Wientjes F, Segal AW. Chronic granulomatous disease. Biochim Biophys Acta 1994; 1227: 1-14.
62. Bayaraktutan U, Blayney L, Shah AM. Molecular characterisation and localisation of the NAD(P)H oxidase components gp91-phox and p22-phox in endothelial cells. Arteriosclerosis, Thrombosis Vascular Biol 2000; 20: 1903-1911.
63. Meyer JW, Schmitt ME. A central role for the endothelial NADPH oxidase in atherosclerosis. FEBS Letters 2000; 472: 1-4.
64. Guzic TJ, West NEJ, Black E, McDonald D, Ratnatunga C, Pillai R et al. Vascular superoxide production by NAD(P)H oxidase. Association with endothelial dysfunction and clinical risk factors. Circulation Res 2000; 86: e85-e90.
65. Czech MP, Corvera S. Signaling mechanisms that regulate glucose transport. J Biol Chem 1999; 274: 1865-1868.
66. Shepherd PR, Kahn BB. Glucose transporters and insulin action - implications for insulin resistance and diabetes mellitus. N Engl J Med 1999; 341: 248-257.
67. Kasuga M, Zick Y, Blithe DL, Crettaz M, Kahn CR. Insulin stimulates tyrosine phosphorylation of the insulin receptor in a cell-free system. Nature 1982; 298: 667-669.
68. Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 2000; 106: 165-169.
69. Sun XJ, Rothenberg P, Kahn CR, Backer JM, Araki E, Wilden PA et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 1991; 352: 73-77.
70. Kanai F, Ito K, Todaka M, Hayashi H, Kamohara S, Ishii K et al. Insulin-stimulated GLUT4 translocation is relevant to the phosphorylation of IRS-1 and the activity of PI3-kinase. Biochem Biophys Res Commun 1993; 195: 762-768.
71. Haruta T, Morris AJ, Rose DW, Nelson JG, Mueckler M, Olefsky JM. Insulin-stimulated GLUT4 translocation is mediated by a divergent intracellular signaling pathway. J Biol Chem 1995; 270: 27991-27994.
72. Hajduch E, Litherland GJ, Hundal HS. Protein kinase B (PKB/Akt) - a key regulator of glucose transport? FEBS Letters 2001; 492: 199-203.
73. Baumann CA, Ribon V, Kanzaki M, Thurmond DC, Mora S, Shigematsu S et al. CAP defines a second signalling pathway required for insulin-stimulated glucose transport. Nature 2000; 407: 202-207.
74. Goodyear LJ, Kahn BB. Exercise, glucose transport, and insulin sensitivity. Annu Rev Med 1998; 49: 235-261.
75. Goodyear LJ, Giorgino F, Sherman LA, Carey J, Smith RJ, Dohm GL. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest 1995; 95: 2195-2204.
76. Virkamaki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 1999; 103: 931-943.
77. Greene MW, Garofalo RS. Positive and negative regulatory role of insulin receptor substrate 1 and 2 (IRS-1 and IRS-2) serine/threonine phosphorylation. Biochemistry 2002; 41: 7082-7091.
78. Pessin JE, Thurmond DC, Elmendorf JS, Coker KJ, Okada S. Molecular basis of insulin-stimulated GLUT4 vesicle trafficking. Location! Location! Location! J Biol Chem 1999; 274: 2593-2596.
79. Saltiel AR, Pessin JE. Insulin signaling pathways in time and space. Trends Cell Biol 2002; 12: 65-71.
80. Petrie JR, Ueda S, Webb DJ, Elliott HL, Connell JM. Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. Circulation 1996; 93: 1331-1333.
81. Laine H, Yki-Jarvinen H, Kirvela O, Tolvanen T, Raitakari M, Solin O et al. Insulin resistance of glucose uptake in skeletal muscle cannot be ameliorated by enhancing endothelium-dependent blood flow in obesity. J Clin Invest 1998; 101: 1156-1162.
82. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601-2610.
83. Balletshofer BM, Rittig K, Enderle MD, Volk A, Maerker E, Jacob S et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000; 101: 1780-1784.
84. Inoue T, Matsunaga R, Sakai Y, Yaguchi I, Takayanagi K, Morooka S. Insulin resistance affects endothelium-dependent acetylcholine-induced coronary artery response. Eur Heart J 2000; 21: 895-900.
85. Winters B, Mo Z, Brooks-Asplund E, Kim S, Shoukas A, Li D et al. Reduction of obesity, as induced by leptin, reverses endothelial dysfunction in obese (Lep(ob)) mice. J Appl Physiol 2000; 89: 2382-2390.
86. Katakam PV, Ujhelyi MR, Hoenig ME, Miller AW. Endothelial dysfunction precedes hypertension in diet-induced insulin resistance. Am J Physiol 1998; 275: R788-792.
87. Abe H, Yamada N, Kamata K, Kuwaki T, Shimada M, Osuga J et al. Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J Clin Invest 1998; 101: 1784-1788.
88. Chisholm DJ, Campbell LV, Kraegen EW. Pathogenesis of the insulin resistance syndrome (syndrome X). Clin Exp Pharmacol Physiol 1997; 24: 782-784.
89. Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 2001; 104: 517-529.
90. Pinkney JH, Stehouwer CD, Coppack SW, Yudkin JS. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes 1997; 46: S9-13.
91. Yki-Jarvinen H, Utriainen T. Insulin-induced vasodilatation: physiology or pharmacology? Diabetologia 1998; 41: 369-379.
92. Montagnani M, Quon MJ. Insulin action in vascular endothelium: potential mechanisms linking insulin resistance with hypertension. Diabetes Obes Metab 2000; 2: 285-292.
93. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000; 105: 311-320.
94. Bjornholm M, Kawano Y, Lehtihet M, Zierath JR. Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation. Diabetes 1997; 46: 524-527.
95. Juan CC, Fang VS, Kwok CF, Perng JC, Chou YC, Ho LT. Exogenous hyperinsulinaemia causes insulin resistance, hyperendothelinaemia, and subsequent hypertension in rats. Metabolism 1999; 48: 465-471.
96. Marban SL, Barr V, Roth J. Hyperinsulinaemia in transgenic mice leads to insulin resistance, receptor down-regulation and glucose intolerance [Abstract]. Diabetes 1990; 39: 59A.
97. Kearney MT, Cowley AJ, Stubbs TA, Macdonald IA. Effect of a physiological insulin infusion on the cardiovascular responses to a high fat meal: evidence supporting a role for insulin in modulating postprandial cardiovascular homeostasis in man. Clin Sci (Lond) 1996; 91: 415-423.
98. Kearney MT, Cowley AJ, Stubbs TA, Evans A, Macdonald IA. Depressor action of insulin on skeletal muscle vasculature: a novel mechanism for postprandial hypotension in the elderly. J Am Coll Cardiol 1998; 31: 209-216.
99. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996; 98: 894-898.
100. Kobayashi T, Kamata K. Effect of chronic insulin treatment on NO production and endothelium-dependent relaxation in aortae from established STZ-induced diabetic rats. Atherosclerosis 2001; 155: 313-320.
101. Hu RM, Levin ER, Pedram A, Frank HJL. Insulin stimulates production and secretion of endothelin from bovine endothelial cells. Diabetes 1993; 42: 351-358.
102. Cleland SJ, Petrie JR, Small M, Elliott HL, Connell JM. Insulin action is associated with endothelial function in hypertension and type 2 diabetes. Hypertension 2000; 35: 507-511.
103. Arcaro G, Cretti A, Balzano S, Lechi A, Muggeo M, Bonora E et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 2002; 105: 576-582.
104. Vehkavaara S, Makimattila S, Schlenzka A, Vakkilainen J, Westerbacka J, Yki-Jarvinen H. Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 2000; 20: 545-550.
105. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
106. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972-978.
107. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-242.
108. Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Connell JM. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond) 2000; 98: 531-535.
109. Hak AE, Stehouwer CD, Bots ML, Polderman KH, Schalkwijk CG, Westendorp IC et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 1999; 19: 1986-1991.
110. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-2415.
111. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-4200.
112. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNF alpha by human muscle. Relationship to insulin resistance. J Clin Invest 1996; 97: 1111-1116.
113. Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 1998; 83: 2907-2910.
114. Winkler G, Lakatos P, Salamon F, Nagy Z, Speer G, Kovacs M et al. Elevated serum TNF-alpha level as a link between endothelial dysfunction and insulin resistance in normotensive obese patients. Diabet Med 1999; 16: 207-211.
115. Bluher M, Kratzsch J, Paschke R. Plasma levels of tumor necrosis factor-alpha, angiotensin II, growth hormone, and IGF-I are not elevated in insulin-resistant obese individuals with impaired glucose tolerance. Diabetes Care 2001; 24: 328-334.
116. Van der Poll T, Romijn JA, Endert E, Borm JJ, Buller HR, Sauerwein HP. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am J Physiol 1991; 261: E457-E465.
117. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 610-614.
118. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999; 245: 621-625.
119. Bedard S, Marcotte B, Marette A. Cytokines modulate glucose transport in skeletal muscle by inducing the expression of inducible nitric oxide synthase. Biochem J 1997; 325: 487-493.
120. Perreault M, Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med 2001; 7: 1138-1143.
121. Myers PR, Parker JL, Tanner MA, Adams HR. Effects of cytokines tumor necrosis factor alpha and interleukin 1 beta on endotoxin-mediated inhibition of endothelium-derived relaxing factor bioactivity and nitric oxide production in vascular endothelium. Shock 1994; 1: 73-78.
122. Wang P, Ba ZF, Chaudry IH. Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol 1994; 266: H2535-H2541.
123. Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997; 96: 3042-3047.
124. De Keulenaer GW, Alexander RW, Ushio-Fukai M, Ishizaka N, Griendling KK. Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. Biochem J 1998; 329: 653-657.
125. Hermann C, Assmus B, Urbich C, Zeiher AM, Dimmeler S. Insulin-mediated stimulation of protein kinase Akt: a potent survival signaling cascade for endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20: 402-409.
126. Yanagisawa M, Kurihara H, Kimura S, Mitsui Y, Yazaki Y, Goto K et al. A novel potent vasoconstrictor peptide produced by endothelial cells. Nature 1988; 332: 411-415.
127. Piatti P, Monti LD, Galli L, Fragasso G, Valsecchi G, Conti M et al. Relationship between endothelin-1 concentration and metabolic alterations typical of the insulin resistance syndrome. Metabolism 2000; 49: 748-752.
128. Irving RJ, Noon JP, Watt GCM, Webb DJ, Walker BR. Activation of the endothelin system in insulin resistance. QJM 2001; 94: 321-326.
129. Lerman A, Edwards BS, Hallett JW, Heblin DM, Sandberg SM, Burnett JJ. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325: 997-1001.
130. Chou YC, Perng JC, Juan CC, Jang SY, Kwok CF, Chen WL et al. Endothelin-1 inhibits insulin-stimulated glucose uptake in isolated rat adipocytes. Biochem Biophys Res Commun 1994; 202: 688-693.
131. Juan CC, Fang VS, Huang Y, Kwok CF, Hsu YP, Ho LT. Endothelin-1 induces insulin resistance in conscious rats. Biochem Biophys Res Commun 1996; 227: 694-699.
132. Ottosson-Seeberger A, Lundberg JM, Alvestrand A, Ahlborg G. Exogenous endothelin-1 causes peripheral insulin resistance in healthy humans. Acta Physiol Scand 1997; 161: 211-220.
133. Jiang ZY, Zhou QL, Chatterjee A, Feener EP, Myers MG Jr, White MF et al. Endothelin-1 modulates insulin signaling through phosphatidyl 3-kinase pathway in vascular smooth muscle cells. Diabetes 1999; 48: 1120-1130.
134. Verma S, Yao L, Stewart DJ, Dumont AS, Anderson TJ, McNeill JH. Endothelin antagonism uncovers insulin-mediated vasorelaxation in vitro and in vivo. Hypertension 2001; 37: 328-333.
135. Verma S, Bhanot S, McNeill JH. Effects of chronic endothelin blockade in hyperinsulinaemic hypertensive rats. Am J Physiol 1995; 269: H2017-H2021.
136. Verma S, Skarsgarrd P, Bhanot S, Yao L, Laher I, McNeill JH. Reactivity of mesenteric arteries from fructose-hypertensive rats to endothelin-1. Am J Hypertens 1997; 10: 1010-1019.
137. Duerrschmidt N, Wippich N, Goettsch W, Broeme H-J, Moraweitz H. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Commun 2000; 269: 713-717.
138. Lind L, Reneland R, Andersson PE, Haenni A, Lithell H. Insulin resistance in essential hypertension is related to plasma renin activity. J Hum Hypertens 1998; 12: 379-382.
139. Weiss D, Sorescu D, Taylor WR. Angiotensin II and atherosclerosis. Am J Cardiol 2001; 87: 25-32.
140. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000; 35: 1270-1277.
141. Ching SF, Hayes LW, Slakey LL. Angiotensin converting enzyme in cultured endothelial cells and growth medium. Relationships to enzyme from kidney and plasma. Biochim Biophys Acta 1981; 657: 222-231.
142. Luscher TF. Endothelial dysfunction: the role and impact of the renin-angiotensin system. Heart 2000; 84: i20-i22; discussion i50.
143. Richey JM, Ader M, Moore D, Bergman RN. Angiotensin II induces insulin resistance independent of changes in interstitial insulin. Am J Physiol 1999; 277: E920-E926.
144. Folli F, Saad MJ, Velloso L, Hansen H, Carandente O, Feener EP et al. Crosstalk between insulin and angiotensin II signalling systems. Exp Clin Endocrinol Diabetes 1999; 107: 133-139.
145. Morris AD, Petrie JR, Anderson J, Connell JM, Donnelly R. Effects of angiotensin II on insulin sensitivity: a placebo-controlled study. Clin Sci (Colch) 1993; 85: 431-436.
146. Fliser D, Arnold U, Kohl B, Hartung R, Ritz E. Angiotensin II enhances insulin sensitivity in healthy volunteers under euglycemic conditions. J Hypertens 1993; 11: 983-988.
147. Katovich MJ, Pachori A. Effects of inhibition of the renin-angiotensin system on the cardiovascular actions of insulin. Diabetes Obes Metab 2000; 2: 3-14.
148. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102: 2434-2440.
149. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-1923.
150. O'Driscoll G, Green D, Maiorana A, Stanton K, Colreavy F, Taylor R. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1999; 33: 1506-1511.
151. Cheetham C, Collis J, O'Driscoll G, Stanton K, Taylor R, Green D. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. J Am Coll Cardiol 2000; 36: 1461-1466.
152. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell 2001; 104: 531-543.
153. Chua SC Jr, Chung WK, Wu-Peng XS, Zhang Y, Liu SM, Tartaglia L et al. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 1996; 271: 994-996.
154. Halaas JL, Gajwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995; 269: 543-546.
155. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387: 903-908.
156. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-295.
157. Donahue RP, Prineas RJ, Donahue RD, Zimmet P, Bean JA, De Courten M et al. Is fasting leptin associated with insulin resistance among nondiabetic individuals? The Miami Community Health Study. Diabetes Care 1999; 22: 1092-1096.
158. Zimmet P, Boyko EJ, Collier GR, de Courten M. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann NY Acad Sci 1999; 892: 25-44.
159. Sierra-Honigmann MR, Nath AK, Murakami C, Garcia-Cardena G, Papapetropoulos A, Sessa WC et al. Biological action of leptin as an angiogenic factor. Science 1998; 281: 1683-1686.
160. Haynes WG, Sivitz WI, Morgan DA, Walsh SA, Mark AL. Sympathetic and cardiorenal actions of leptin. Hypertension 1997; 30: 619-623.
161. Bouloumie A, Marumo T, Lafontan M, Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J 1999; 13: 1231-1238.
162. Yamagishi Si S, Edelstein D, Du Xl X, Kaneda Y, Guzman M, Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 2001; 276: 25096-25100.
163. Kimura K, Tsuda K, Baba A, Kawabe T, Boh-oka S, Ibata M et al. Involvement of nitric oxide in endothelium-dependent arterial relaxation by leptin. Biochem Biophys Res Commun 2000; 273: 745-749.
164. Lembo G, Vecchione C, Fratta L, Marino G, Trimarco V, d'Amati G et al. Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes 2000; 49: 293-297.
165. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3-10.
166. Yki-Jarvinen H, Puhakainen I, Koivisto VA. Effect of free fatty acids on glucose uptake and nonoxidative glycolysis across human forearm tissues in the basal state and during insulin stimulation. J Clin Endocrinol Metab 1991; 72: 1268-1277.
167. Santomauro AT, Boden G, Silva ME, Rocha DM, Santos RF, Ursich MJ et al. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 1999; 48: 1836-1841.
168. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996; 97: 2859-2865.
169. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999; 103: 253-259.
170. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 1997; 100: 1230-1239.
171. Lind L, Fugmann A, Branth S, Vessby B, Millgard J, Berne C et al. The impairment in endothelial function induced by non-esterified fatty acids can be reversed by insulin. Clin Sci (Colch) 2000; 99: 169-174.
172. Lundman P, Eriksson M, Schenck-Gustafsson K, Karpe F, Tornvall P. Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. Circulation 1997; 96: 3266-3268.
173. de Man FH, Weverling-Rijnsburger AWE, van der Laarse A, Smelt AHM, Jukema JW, Blauw GJ. Not acute but chronic hypertriglyceridemia is associated with impaired endothelium-dependent vasodilation: reversal after lipid-lowering therapy by Atorvastatin. Arterioscler Thromb Vasc Biol 2000; 20: 744-750.
174. Kearney M, Chowienczyk PJ, Brett SE, Sutcliffe A, Ritter JM, Shah AM. Acute haemodynamic effects of lipolysis-induced increases of free fatty acids in healthy men. Clin Sci (Colch) 2002; 102: 495-500.
175. Davda RK, Stepniakowski KT, Lu G, Ullian ME, Goodfriend TL, Egan BM. Oleic acid inhibits endothelial nitric oxide synthase by a protein kinase C-independent mechanism. Hypertension 1995; 26: 764-770.
176. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000; 49: 1939-1945.
177. Laight DW, Kengatharan KM, Gopaul NK, Anggard EE, Carrier MJ. Investigation of oxidant stress and vasodepression to glyceryl trinitrate in the obese Zucker rat in vivo. Br J Pharmacol 1998; 125: 895-901.
178. Paolisso G, Giugliano D. Oxidative stress and insulin action: is there a relationship? Diabetologia 1996; 39: 357-363.
179. Paolisso G, D'Amore A, Volpe C, Balbi V, Saccomanno F, Galzerano D et al. Evidence for a relationship between oxidative stress and insulin action in non-insulin-dependent (type II) diabetic patients. Metabolism 1994; 43: 1426-1429.
180. Laight DW, Desai KM, Gopaul NK, Anggard EE, Carrier MJ. Pro-oxidant challenge in vivo provokes the onset of NIDDM in the insulin resistant obese Zucker rat. Br J Pharmacol 1999; 128: 269-271.
181. Rudich A, Tirosh A, Potashnik R, Hemi R, Kanety H, Bashan N. Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes 1998; 47: 1562-1569.
182. Hansen LL, Ikeda Y, Olsen GS, Busch AK, Mosthaf L. Insulin signaling is inhibited by micromolar concentrations of H(2)O(2). Evidence for a role of H(2)O(2) in tumor necrosis factor alpha-mediated insulin resistance. J Biol Chem 1999; 274: 25078-25084.
183. Kashiwagi A, Shinozaki K, Nishio Y, Maegawa H, Maeno Y, Kanazawa A et al. Endothelium-specific activation of NAD(P)H oxidase in aortas of exogenously hyperinsulinemic rats. Am J Physiol 1999; 277: E976-E983.
184. Shinozaki K, Kashiwagi A, Nishio Y, Okamura T, Yoshida Y, Masada M et al. Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2-imbalance in insulin-resistant rat aorta. Diabetes 1999; 48: 2437-2445.
185. Abou-Donia MM, Duch DS, Nichol CA, Viveros OH. Hormonal regulation of guanosine triphosphate cyclohydrolase activity and biopterin levels in the rat adrenal cortex. Endocrinology 1983; 112: 2088-2094.
186. Shinozaki K, Nishio Y, Okamura T, Yoshida Y, Maegawa H, Kojima H et al. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ Res 2000; 87: 566-573.
187. Ross R, Dagnone D, Jones PJ, Smith H, Paddags A, Hudson R et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med 2000; 133: 92-103.
188. Riccardi G, Rivellese AA. Dietary treatment of the metabolic syndrome - the optimal diet. Br J Nutr 2000; 83: S143-S148.
189. Lavrencic A, Salobir BG, Keber I. Physical training improves flow-mediated dilation in patients with the polymetabolic syndrome. Arterioscler Thromb Vasc Biol 2000; 20: 551-555.
190. Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res 2001; 49: 281-287.
191. John S, Delles C, Jacobi J, Schlaich MP, Schneider M, Schmitz G et al. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol 2001; 37: 1351-1358.
192. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481-487.
193. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999; 33: 234-241.
194. Yamamoto A, Hoshi K, Ichihara K. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes. Eur J Pharmacol 1998; 361: 143-149.
195. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20: 61-69.
196. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357-362.
197. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999; 353: 983-984.
198. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996; 94: 258-265.
199. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
200. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
201. Nawano M, Anai M, Funaki M, Kobayashi H, Kanda A, Fukushima Y et al. Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat. Metabolism 1999; 48: 1248-1255.
202. Henriksen EJ, Jacob S, Kinnick TR, Youngblood EB, Schmit MB, Dietze GJ. ACE inhibition and glucose transport in insulin-resistant muscle: roles of bradykinin and nitric oxide. Am J Physiol 1999; 277: R332-R336.
203. Isami S, Kishikawa H, Araki E, Uehara M, Kaneko K, Shirotani T et al. Bradykinin enhances GLUT4 translocation through the increase of insulin receptor tyrosine kinase in primary adipocytes: evidence that bradykinin stimulates the insulin signalling pathway. Diabetologia 1996; 39: 412-420.
204. Dietze GJ, Wicklmayr M, Rett K, Jacob S, Henriksen EJ. Potential role of bradykinin in forearm muscle metabolism in humans. Diabetes 1996; 45: S110-S114.
205. Duka I, Shenouda S, Johns C, Kintsurashvili E, Gavras I, Gavras H. Role of the B(2) receptor of bradykinin in insulin sensitivity. Hypertension 2001; 38: 1355-1360.
206. De Mattia G, Ferri C, Laurenti O, Cassone-Faldetta M, Piccoli A, Santucci A. Circulating catecholamines and metabolic effects of captopril in NIDDM patients. Diabetes Care 1996; 19: 226-230.
207. Wiggam MI, Hunter SJ, Atkinson AB, Ennis CN, Henry JS, Browne JN et al. Captopril does not improve insulin action in essential hypertension: a double-blind placebo-controlled study. J Hypertens 1998; 16: 1651-1657.
208. Petrie JR, Morris AD, Ueda S, Small M, Donnelly R, Connell JM et al. Trandolapril does not improve insulin sensitivity in patients with hypertension and type 2 diabetes: a double-blind, placebo-controlled crossover trial. J Clin Endocrinol Metab 2000; 85: 1882-1889.
209. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720.
210. Fogari R, Zoppi A, Lazzari P, Preti P, Mugellini A, Corradi L et al. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol 1998; 32: 616-620.
211. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996; 97: 22-28.
212. Hirai N, Kawano H, Hirashima O, Motoyama T, Moriyama Y, Sakamoto T et al. Insulin resistance and endothelial dysfunction in smokers: effects of vitamin C. Am J Physiol Heart Circ Physiol 2000; 279: H1172-H1178.
213. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328: 1450-1456.
214. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347: 781-786.
215. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 154-160.
216. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23-33.
217. Scheen AJ, Letiexhe MR, Lefebvre PJ. Short administration of metformin improves insulin sensitivity in android obese subjects with impairec glucose tolerance. Diabet Med 1995; 12: 985-989.
218. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174.
219. Katakam PV, Ujhelyi MR, Hoenig M, Miller AW. Metformin improves vascular function in insulin-resistant rats. Hypertension 2000; 35: 108-112.
220. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001; 37: 1344-1350.
221. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-665.
222. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 2000; 106: 467-472.
223. Kahn CR, Chen L, Cohen SE. Unraveling the mechanism of action of thiazolidinediones. J Clin Invest 2000; 106: 1305-1307.
224. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
225. Buchan KW, Hassall DG. PPAR agonists as direct modulators of the vessel wall in cardiovascular disease. Med Res Rev 2000; 20: 350-366.
226. Tack CJ, Ong MK, Lutterman JA, Smits P. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone. Diabetologia 1998; 41: 569-576.
227. Walker AB, Chattington PD, Buckingham RE, Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 1999; 48: 1448-1453.
228. Avena R, Mitchell ME, Nylen ES, Curry KM, Sidawy AN. Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. J Vasc Surg 1998; 28: 1024-1031; discussion 1031-1032.
229. Naderali EK, Pickavance LC, Wilding JP, Doyle PJ, Williams G. Troglitazone corrects metabolic changes but not vascular dysfunction in dietary-obese rats. Eur J Pharmacol 2001; 416: 133-139.